3DMed Completes $225 Million Round for Immunotherapy Candidates

3D Medicines, a Beijing clinical-stage biopharma, completed a $225 million funding. Two years ago, 3DMed spun off its diagnostics business into 3D Diagnostics and now concentrates on development of immunotherapy drugs. In 2017, 3DMed agreed to conduct the clinical trials and commercialization of Alphamab's envafolimab (KN035), a subcutaneous injection PD-L1 checkpoint inhibitor. The candidate has started clinical trials in China , the US and Japan .  The company's funding was co-led by China Capital Management and Efung Capital, a biomedical venture capital firm. More details.... Share this with colleagues: // //